Cargando…

Cost-Consequence Analysis of Using Cangrelor in High Angiographic Risk Percutaneous Coronary Intervention Patients: A US Hospital Perspective

OBJECTIVES: The objective of this study was to evaluate a US hospital’s cost implications and outcomes of cangrelor use in percutaneous coronary intervention (PCI) patients with two or more angiographic high-risk features (HRFs), including avoidance of oral P2Y(12) inhibitor pretreatment in patients...

Descripción completa

Detalles Bibliográficos
Autores principales:	Jensen, Ivar S., Wu, Elizabeth, Cyr, Philip L., Claussen, Marc, Winkler, Thomas, Salahuddin, Khalid, Prats, Jayne, Mahaffey, Kenneth W., Gibson, Charles Michael, Steg, Philippe Gabriel, Stone, Gregg W., Bhatt, Deepak L.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer International Publishing 2021
Materias:	Original Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8748330/ https://www.ncbi.nlm.nih.gov/pubmed/34331235 http://dx.doi.org/10.1007/s40256-021-00491-9

Ejemplares similares

Efficacy and Safety of Cangrelor in Women Versus Men During Percutaneous Coronary Intervention: Insights From the Cangrelor versus Standard Therapy to Achieve Optimal Management of Platelet Inhibition (CHAMPION PHOENIX) Trial
por: O’Donoghue, Michelle L., et al.
Publicado: (2016)

Consistent Reduction in Periprocedural Myocardial Infarction With Cangrelor as Assessed by Multiple Definitions: Findings From CHAMPION PHOENIX (Cangrelor Versus Standard Therapy to Achieve Optimal Management of Platelet Inhibition)
por: Cavender, Matthew A., et al.
Publicado: (2016)

Ischemic Events Occur Early in Patients Undergoing Percutaneous Coronary Intervention and Are Reduced With Cangrelor: Findings From CHAMPION PHOENIX
por: Cavender, Matthew A., et al.
Publicado: (2021)

The efficacy and safety of cangrelor in single vessel vs multivessel percutaneous coronary intervention: Insights from CHAMPION PHOENIX
por: Yong, Celina M., et al.
Publicado: (2019)

Variation in Patient Profiles and Outcomes in US and Non-US Subgroups of the Cangrelor Versus Standard Therapy to Achieve Optimal Management of Platelet Inhibition (CHAMPION) PHOENIX Trial
por: Vaduganathan, Muthiah, et al.
Publicado: (2016)

The effect of cangrelor and access site on ischaemic and bleeding events: insights from CHAMPION PHOENIX
por: Gutierrez, J. Antonio, et al.
Publicado: (2016)

Cangrelor: Clinical Data, Contemporary Use, and Future Perspectives
por: De Luca, Leonardo, et al.
Publicado: (2021)

Impact of lesion complexity on peri-procedural adverse events and the benefit of potent intravenous platelet adenosine diphosphate receptor inhibition after percutaneous coronary intervention: core laboratory analysis from 10 854 patients from the CHAMPION PHOENIX trial
por: Stone, Gregg W, et al.
Publicado: (2018)

Feasibility and safety of cangrelor in patients with suboptimal P2Y(12) inhibition undergoing percutaneous coronary intervention: the Dutch Cangrelor registry
por: Selvarajah, Abi, et al.
Publicado: (2021)

Feasibility and safety of cangrelor in patients with suboptimal P2Y(12) inhibition undergoing percutaneous coronary intervention: rationale of the Dutch Cangrelor Registry
por: Selvarajah, A., et al.
Publicado: (2021)

Efficacy of Cangrelor as Bridging Therapy Post PCI
por: Khan, Abdul A., et al.
Publicado: (2020)

P2Y(12) Receptor Function and Response to Cangrelor in Neonates With Cyanotic Congenital Heart Disease
por: Kaza, Elisabeth A., et al.
Publicado: (2017)

Safety of Low Dose Intravenous Cangrelor in Acute Ischemic Stroke: A Case Series
por: Salahuddin, Hisham, et al.
Publicado: (2021)

Cangrelor Use Patterns and Transition to Oral P2Y(12) Inhibitors Among Patients With Myocardial Infarction: Initial Results From the CAMEO Registry
por: Rymer, Jennifer A., et al.
Publicado: (2022)

Real-World Experience with Cangrelor as Adjuvant to Percutaneous Coronary Intervention: A Single-Centre Observational Study
por: Thim, Troels, et al.
Publicado: (2023)

Cangrelor Use in Routine Practice: A Two-Center Experience
por: van der Sangen, Niels M. R., et al.
Publicado: (2021)

Comparison of myocardial reperfusion between intracoronary versus intravenous cangrelor administration in patients undergoing primary percutaneous coronary intervention
por: Muraca, Iacopo, et al.
Publicado: (2023)

Urgent Revascularization of the Left Proximal Circumflex Following Cessation of Cangrelor Within Six Hours of Procedure
por: Huang, Sherri, et al.
Publicado: (2023)

Use of cangrelor in patients with acute coronary syndromes undergoing percutaneous coronary intervention: Study design and interim analysis of the ARCANGELO study
por: De Luca, Leonardo, et al.
Publicado: (2022)

Safety of cangrelor and transition to oral P2Y(12) inhibitors in patients undergoing percutaneous coronary intervention: the ARCANGELO study
por: De Luca, Leonardo, et al.
Publicado: (2023)

Cangrelor bridging strategy for liver damage after mechanical chest compression
por: Cereda, Alberto Francesco, et al.
Publicado: (2019)

Cangrelor or Clopidogrel in Patients with Type 2 Diabetes Mellitus Undergoing Percutaneous Coronary Intervention: A Meta-Analysis of Randomized Controlled Trials
por: Lu, Hongtao, et al.
Publicado: (2019)

Intravenous antiplatelet therapies (glycoprotein IIb/IIIa receptor inhibitors and cangrelor) in percutaneous coronary intervention: from pharmacology to indications for clinical use
por: Capodanno, Davide, et al.
Publicado: (2019)

Cangrelor ameliorates CLP-induced pulmonary injury in sepsis by inhibiting GPR17
por: Luo, Qiancheng, et al.
Publicado: (2021)

Comparative effectiveness of Cangrelor in patients with acute coronary syndrome undergoing percutaneous coronary intervention: an observational investigation from the M.O.Ca. registry
por: Pepe, Martino, et al.
Publicado: (2023)

Short-Term Consequences of Angiographically-Confirmed Coronary Stent Thrombosis
por: Kohn, Christine G., et al.
Publicado: (2013)

Cangrelor Induces More Potent Platelet Inhibition without Increasing Bleeding in Resuscitated Patients
por: Prüller, Florian, et al.
Publicado: (2018)

Advanced pharmacodynamics of cangrelor in healthy volunteers: a dose-finding, open-label, pilot trial
por: Gelbenegger, Georg, et al.
Publicado: (2022)

The reduction in cardiovascular risk in REDUCE-IT is due to eicosapentaenoic acid in icosapent ethyl
por: Steg, Ph Gabriel, et al.
Publicado: (2021)

Adenosine Receptor Agonist HE-NECA Enhances Antithrombotic Activities of Cangrelor and Prasugrel in vivo by Decreasing of Fibrinogen Density in Thrombus
por: Polak, Dawid, et al.
Publicado: (2021)

Pharmacokinetic and Pharmacodynamic Profile of a Novel Phospholipid Aspirin Formulation
por: Angiolillo, Dominick J., et al.
Publicado: (2022)

Correction to: A Novel Bridging Strategy for Patients Undergoing Emergent Non-Cardiac Surgery with a Recent Coronary Stent
por: Bruck, Cierra, et al.
Publicado: (2018)

A Novel Bridging Strategy for Patients Undergoing Emergent Non-Cardiac Surgery with a Recent Coronary Stent
por: Bruck, Cierra, et al.
Publicado: (2018)

Efficacy of a Combined Antiplatelet Therapy Is Not Affected by a Simultaneous Binding of Cangrelor and PSB 0777 to Albumin
por: Wzorek, Joanna, et al.
Publicado: (2021)

Cost–consequence analysis of (18)F-fluciclovine for the staging of recurrent prostate cancer
por: Jensen, Ivar S, et al.
Publicado: (2020)

Angiographic Lesion Complexity Score and In-Hospital Outcomes after Percutaneous Coronary Intervention
por: Endo, Ayaka, et al.
Publicado: (2015)

Gender based differences in clinical and Angiographic characteristics and outcomes of Acute Coronary Syndrome (ACS) in Asian population
por: Altaf, Afrasyab, et al.
Publicado: (2019)

The use of cangrelor with heparin for left ventricular assist device implantation in a patient with acute heparin-induced thrombocytopenia
por: Gernhofer, Yan K., et al.
Publicado: (2018)

Correlation of Admission Heart Rate With Angiographic and Clinical Outcomes in Patients With Right Coronary Artery ST‐Segment Elevation Myocardial Infarction Undergoing Primary Percutaneous Coronary Intervention: HORIZONS‐AMI (The Harmonizing Outcomes With Revascularization and Stents in Acute Myocardial Infarction) Trial
por: Kosmidou, Ioanna, et al.
Publicado: (2017)

Hemorrhagic complications after percutaneous nephrolithotomy: angiographic diagnosis and management by transcatheter arterial embolization
por: Fornazari, Vinicius Adami Vayego, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_vl1h3g2fqcddtcok7eduq8cau5